

Andrea Amalfitano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2145654/publications.pdf>

Version: 2024-02-01

69
papers

2,983
citations

136950

32
h-index

168389

53
g-index

69
all docs

69
docs citations

69
times ranked

3150
citing authors

#	ARTICLE	IF	CITATIONS
1	Adenoviral delivery of an immunomodulatory protein to the tumor microenvironment controls tumor growth. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 180-193.	4.4	5
2	ERAP1 is a critical regulator of inflammasome-mediated proinflammatory and ER stress responses. <i>BMC Immunology</i> , 2022, 23, 9.	2.2	7
3	SLAMF7 Signaling Reprograms T Cells toward Exhaustion in the Tumor Microenvironment. <i>Journal of Immunology</i> , 2021, 206, 193-205.	0.8	40
4	Absence of ERAP1 in B Cells Increases Susceptibility to Central Nervous System Autoimmunity, Alters B Cell Biology, and Mechanistically Explains Genetic Associations between ERAP1 and Multiple Sclerosis. <i>Journal of Immunology</i> , 2021, , j2100813.	0.8	2
5	Î”9-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7â€“Stimulated Human Coculture. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 371, 191-201.	2.5	43
6	Imiquimod and interferon-alpha augment monocyte-mediated astrocyte secretion of MCP-1, IL-6 and IP-10 in a human co-culture system. <i>Journal of Neuroimmunology</i> , 2019, 333, 576969.	2.3	13
7	The role of ERAP1 in autoinflammation and autoimmunity. <i>Human Immunology</i> , 2019, 80, 302-309.	2.4	17
8	SLAM Family Receptor Signaling in Viral Infections: HIV and Beyond. <i>Vaccines</i> , 2019, 7, 184.	4.4	8
9	SLAMF7 Is a Critical Negative Regulator of IFN-Î±â€“Mediated CXCL10 Production in Chronic HIV Infection. <i>Journal of Immunology</i> , 2019, 202, 228-238.	0.8	29
10	In vitro Infection of Primary Human Monocytes with HIV-1. <i>Bio-protocol</i> , 2019, 9, .	0.4	2
11	Compound heterozygosity for loss-of-function <i>FARSB</i> variants in a patient with classic features of recessive aminoacyl-tRNA synthetase-related disease. <i>Human Mutation</i> , 2018, 39, 834-840.	2.5	30
12	ELOVL4-Mediated Production of Very Long-Chain Ceramides Stabilizes Tight Junctions and Prevents Diabetes-Induced Retinal Vascular Permeability. <i>Diabetes</i> , 2018, 67, 769-781.	0.6	41
13	HIV-infected cannabis users have lower circulating CD16+ monocytes and IFN-Î³-inducible protein 10 levels compared with nonusing HIV patients. <i>Aids</i> , 2018, 32, 419-429.	2.2	78
14	ERAP1 deficient mice have reduced Type 1 regulatory T cells and develop skeletal and intestinal features of Ankylosing Spondylitis. <i>Scientific Reports</i> , 2018, 8, 12464.	3.3	24
15	Decreased Vector Gene Expression from E2b Gene-Deleted Adenovirus Serotype 5 Vaccines Intensifies Proinflammatory Immune Responses. <i>Vaccine Journal</i> , 2017, 24, .	3.1	2
16	Mice expressing human ERAP1 variants associated with ankylosing spondylitis have altered T-cell repertoires and NK cell functions, as well as increased <i>in utero</i> and perinatal mortality. <i>International Immunology</i> , 2017, 29, 277-289.	4.0	13
17	Current and Future Treatments for Lysosomal Storage Disorders. <i>Current Treatment Options in Neurology</i> , 2017, 19, 45.	1.8	9
18	Methods to Mitigate Immune Responses to Adenoviral Vectors. , 2016, , 391-422.		2

#	ARTICLE	IF	CITATIONS
19	CRACC-targeting Fc-fusion protein induces activation of NK cells and DCs and improves T cell immune responses to antigenic targets. <i>Vaccine</i> , 2016, 34, 3109-3118.	3.8	6
20	In Vivo Synthesis of Cyclic-di-GMP Using a Recombinant Adenovirus Preferentially Improves Adaptive Immune Responses against Extracellular Antigens. <i>Journal of Immunology</i> , 2016, 196, 1741-1752.	0.8	13
21	Recent advances in gene therapy for lysosomal storage disorders. <i>The Application of Clinical Genetics</i> , 2015, 8, 157.	3.0	36
22	Autoimmune Disease-Associated Variants of Extracellular Endoplasmic Reticulum Aminopeptidase 1 Induce Altered Innate Immune Responses by Human Immune Cells. <i>Journal of Innate Immunity</i> , 2015, 7, 275-289.	3.8	40
23	Strengthened tumor antigen immune recognition by inclusion of a recombinant Eimeria antigen in therapeutic cancer vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 479-491.	4.2	2
24	Stimulation of Innate Immunity by In Vivo Cyclic di-GMP Synthesis Using Adenovirus. <i>Vaccine Journal</i> , 2014, 21, 1550-1559.	3.1	12
25	ERAP1 functions override the intrinsic selection of specific antigens as immunodominant peptides, thereby altering the potency of antigen-specific cytolytic and effector memory T-cell responses. <i>International Immunology</i> , 2014, 26, 685-695.	4.0	16
26	Manipulation of EAT-2 expression promotes induction of multiple beneficial regulatory and effector functions of the human innate immune system as a novel immunomodulatory strategy. <i>International Immunology</i> , 2014, 26, 291-303.	4.0	13
27	Rationally designed inhibitor targeting antigen-trimming aminopeptidases enhances antigen presentation and cytotoxic T-cell responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 19890-19895.	7.1	107
28	Endoplasmic reticulum aminopeptidase-1 alleles associated with increased risk of ankylosing spondylitis reduce HLA-B27 mediated presentation of multiple antigens. <i>Autoimmunity</i> , 2013, 46, 497-508.	2.6	56
29	Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1293-1301.	4.2	76
30	Activation of human natural killer cells by the novel innate immune modulator recombinant Eimeria antigen. <i>Human Immunology</i> , 2013, 74, 916-926.	2.4	6
31	Endoplasmic Reticulum Aminopeptidase-1 Functions Regulate Key Aspects of the Innate Immune Response. <i>PLoS ONE</i> , 2013, 8, e69539.	2.5	41
32	Response to Reuser. <i>Genetics in Medicine</i> , 2012, 14, 827-828.	2.4	18
33	Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice. <i>Vaccine</i> , 2012, 30, 1492-1501.	3.8	29
34	Malaria vaccines: Focus on adenovirus based vectors. <i>Vaccine</i> , 2012, 30, 5191-5198.	3.8	32
35	Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: Need for agents to target antibody-secreting plasma cells. <i>Molecular Genetics and Metabolism</i> , 2012, 105, 677-680.	1.1	59
36	Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naïve and Adenovirus (Ad5) immune mice. <i>Malaria Journal</i> , 2012, 11, 209.	2.3	11

#	ARTICLE	IF	CITATIONS
37	Vaccines Expressing the Innate Immune Modulator EAT-2 Elicit Potent Effector Memory T Lymphocyte Responses despite Pre-Existing Vaccine Immunity. <i>Journal of Immunology</i> , 2012, 189, 1349-1359.	0.8	15
38	Gene Therapy for Lysosomal Storage Diseases: Progress, Challenges and Future Prospects. <i>Current Pharmaceutical Design</i> , 2011, 17, 2558-2574.	1.9	32
39	Use of DAF-Displaying Adenovirus Vectors Reduces Induction of Transgene- and Vector-Specific Adaptive Immune Responses in Mice. <i>Human Gene Therapy</i> , 2011, 22, 1083-1094.	2.7	11
40	Sublingual Administration of an Adenovirus Serotype 5 (Ad5)-Based Vaccine Confirms Toll-Like Receptor Agonist Activity in the Oral Cavity and Elicits Improved Mucosal and Systemic Cell-Mediated Responses against HIV Antigens despite Preexisting Ad5 Immunity. <i>Vaccine Journal</i> , 2011, 18, 150-160.	3.1	44
41	Cutting Edge: Coding Single Nucleotide Polymorphisms of Endoplasmic Reticulum Aminopeptidase 1 Can Affect Antigenic Peptide Generation In Vitro by Influencing Basic Enzymatic Properties of the Enzyme. <i>Journal of Immunology</i> , 2011, 186, 1909-1913.	0.8	122
42	Expression of the SLAM Family of Receptors Adapter EAT-2 as a Novel Strategy for Enhancing Beneficial Immune Responses to Vaccine Antigens. <i>Journal of Immunology</i> , 2011, 186, 722-732.	0.8	32
43	TRIF Is a Critical Negative Regulator of TLR Agonist Mediated Activation of Dendritic Cells In Vivo. <i>PLoS ONE</i> , 2011, 6, e22064.	2.5	12
44	Vaccine Platforms Combining Circumsporozoite Protein and Potent Immune Modulators, rEA or EAT-2, Paradoxically Result in Opposing Immune Responses. <i>PLoS ONE</i> , 2011, 6, e24147.	2.5	13
45	Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo. <i>Blood</i> , 2010, 116, 1669-1677.	1.4	37
46	A New Adenovirus Based Vaccine Vector Expressing an <i>Eimeria tenella</i> Derived TLR Agonist Improves Cellular Immune Responses to an Antigenic Target. <i>PLoS ONE</i> , 2010, 5, e9579.	2.5	33
47	Improving Adenovirus Based Gene Transfer: Strategies to Accomplish Immune Evasion. <i>Viruses</i> , 2010, 2, 2013-2036.	3.3	20
48	Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 1521-1531.	3.1	81
49	Transient Pretreatment With Glucocorticoid Ablates Innate Toxicity of Systemically Delivered Adenoviral Vectors Without Reducing Efficacy. <i>Molecular Therapy</i> , 2009, 17, 685-696.	8.2	99
50	A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses. <i>Immunology Letters</i> , 2009, 122, 44-51.	2.5	36
51	Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity. <i>Vaccine</i> , 2009, 27, 6394-6398.	3.8	44
52	Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system. <i>Virology</i> , 2008, 374, 453-467.	2.4	30
53	Adenovirus vector induced innate immune responses: Impact upon efficacy and toxicity in gene therapy and vaccine applications. <i>Virus Research</i> , 2008, 132, 1-14.	2.2	204
54	Adenovirus Vector-Induced Innate Inflammatory Mediators, MAPK Signaling, As Well As Adaptive Immune Responses Are Dependent upon Both TLR2 and TLR9 In Vivo. <i>Journal of Immunology</i> , 2008, 181, 2134-2144.	0.8	174

#	ARTICLE	IF	CITATIONS
55	Adenovirus Infection Triggers a Rapid, MyD88-Regulated Transcriptome Response Critical to Acute-Phase and Adaptive Immune Responses In Vivo. <i>Journal of Virology</i> , 2007, 81, 1796-1812.	3.4	135
56	Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the toll-like receptor pathway in A549 cells. <i>Virology</i> , 2007, 358, 357-372.	2.4	77
57	Fully Deleted Adenovirus Persistently Expressing GAA Accomplishes Long-Term Skeletal Muscle Glycogen Correction in Tolerant and Nontolerant GSD-II Mice. <i>Molecular Therapy</i> , 2006, 13, 127-134.	8.2	42
58	Multiple Innate Inflammatory Responses Induced after Systemic Adenovirus Vector Delivery Depend on a Functional Complement System. <i>Molecular Therapy</i> , 2006, 14, 588-598.	8.2	96
59	Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA. <i>Journal of Gene Medicine</i> , 2005, 7, 171-178.	2.8	30
60	Utilization of adenovirus vectors for multiple gene transfer applications. <i>Methods</i> , 2004, 33, 173-178.	3.8	30
61	Molecular Therapy: The Journal of the American Society of Gene Therapy Gene Function and Disease. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 622.	7.4	1
62	Use of multiply deleted adenovirus vectors to probe adenovirus vector performance and toxicities. <i>Current Opinion in Molecular Therapeutics</i> , 2003, 5, 362-6.	2.8	4
63	Efficacy of Gene Therapy for a Prototypical Lysosomal Storage Disease (GSD-II) Is Critically Dependent on Vector Dose, Transgene Promoter, and the Tissues Targeted for Vector Transduction. <i>Molecular Therapy</i> , 2002, 5, 436-446.	8.2	62
64	Separating Fact from Fiction: Assessing the Potential of Modified Adenovirus Vectors for Use in Human Gene Therapy. <i>Current Gene Therapy</i> , 2002, 2, 111-133.	2.0	123
65	Dystrophin Expression in Muscle Following Gene Transfer with a Fully Deleted ("Gutted") Adenovirus Is Markedly Improved by Trans-Acting Adenoviral Gene Products. <i>Human Gene Therapy</i> , 2001, 12, 1741-1755.	2.7	56
66	Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein. <i>Journal of Gene Medicine</i> , 2000, 2, 250-259.	2.8	57
67	Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein. , 2000, 2, 250.		2
68	Persistence of an [E1-, Polymerase-] Adenovirus Vector Despite Transduction of a Neoantigen into Immune-Competent Mice. <i>Human Gene Therapy</i> , 1999, 10, 355-364.	2.7	57
69	Production and Characterization of Improved Adenovirus Vectors with the E1, E2b, and E3 Genes Deleted. <i>Journal of Virology</i> , 1998, 72, 926-933.	3.4	234